News | May 14, 2025
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Prithwish has close to 28 years of experience in a Commercial role
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Subscribe To Our Newsletter & Stay Updated
